title: Clinical study of Butylphthalide combined with Xue Shuan Tong on serum inflammatory factors and prognosis effect of patients with cerebral infarction.
abstract: To investigate the effect of Butylphthalide and Xue Shuan Tong on serum inflammatory factors and prognosis of patients with cerebral infarction. One hundred and twenty patients with acute cerebral infarction were randomly divided into control group, Butylphthalide group and Xue Shuan Tong group, with 40 patients in each group. Conventional therapy was performed in the control group; On the basis of conventional therapy, 100ml Butylphthalide intravenously twice a day was administrated among patients in Butylphthalide group; On the basis of conventional therapy, 250ml 0.9% NaCl intravenously once a day was conducted among patients in Xue Shuan Tong group. A treatment course of continuous 7 days was taken in the three groups. The serum levels of IL-2 and CGRP were detected for patients in the three groups before and after treatment. Carotid plaque thickness and size as well as intima-media thickness were detected by ultrasonic testing for patients in three groups before treatment and 90 days after follow-up. The NIHSS, Barthel and MRS scoring were performed for all the patients after 90-day follow-up to evaluate the prognosis. After treatment, differences in the levels of IL-2 and CGRP for patients in the three groups showed statistical significance (P<0.05), while the levels of IL-2 and CGRP in Xue Shuan Tong group were significantly higher than those in the other two groups (P<0.05). After 7-day treatment, plaque size and thickness in Xue Shuan Tong group and Butylphthalide group were significantly reduced, compared with those before treatment (P<0.05), but no significant differences was shown in the plaque size and thickness between Xue Shuan Tong group and Butylphthalide group (P>0.05) .The CA-IMT in Xue Shuan Tong group and Butylphthalide group was significantly reduced after treatment, and that in Butylphthalide group was significantly larger than that in Xue Shuan Tong group (P<0.05). After 90-day follow-up, NIHSS scores in Butylphthalide group were significantly less than those in the other two groups (P<0.05). After 90-day follow-up, Barthel scores in Butylphthalide group and Xue Shuan Tong group were significantly larger than those in control group (P<0.05), while differences between Butylphthalide group and Xue Shuan Tong group indicated no statistical significance (P>0.05). There were significant differences in MRS scores among patients in the three groups after 90-day follow-up (P<0.05). Butylphthalide and Xue Shuan Tong are clinically effective in treating acute cerebral infarction. Butylphthalide has significant efficacy in inhibiting inflammation and improving prognosis of neurological function, while Xue Shuan Tong has obvious effect in improving carotid intima-media thickness.
authors.affiliation: The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China.
authors.forename: Ran
authors.initials: R
authors.lastname: Du
authors.affiliation: The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China.
authors.forename: Jun Fang
authors.initials: JF
authors.lastname: Teng
authors.affiliation: The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China.
authors.forename: Xin Yu
authors.initials: XY
authors.lastname: Zhao
authors.affiliation: The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China.
authors.forename: Zhao Bo
authors.initials: ZB
authors.lastname: Shi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001572:Benzofurans / Q000627:therapeutic use*; D015740:Calcitonin Gene-Related Peptide / Q000097:blood; D002339:Carotid Arteries / Q000473:pathology; D059168:Carotid Intima-Media Thickness; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000503:physiopathology; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000503:physiopathology; D007376:Interleukin-2 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000209:etiology / Q000503:physiopathology; D058226:Plaque, Atherosclerotic / Q000473:pathology; D011379:Prognosis
chemical_list: D001572:Benzofurans; D004365:Drugs, Chinese Herbal; D007376:Interleukin-2; C519374:Panax notoginseng extract; C027125:3-n-butylphthalide; D015740:Calcitonin Gene-Related Peptide